<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04959305</url>
  </required_header>
  <id_info>
    <org_study_id>HM-APOLLO-202</org_study_id>
    <nct_id>NCT04959305</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension</brief_title>
  <acronym>HM_APOLLO</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Parallel, Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, randomized, double-blind, parallel, phase 2 study to explore the dose of&#xD;
      HCP1803 in patients with essential hypertension&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in sitting systolic blood pressure</measure>
    <time_frame>baseline, 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sitting systolic blood pressure</measure>
    <time_frame>baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sitting distolic blood pressure</measure>
    <time_frame>baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving blood pressure control</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responder</measure>
    <time_frame>baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pulse pressure(sitSBP - sitDBP)</measure>
    <time_frame>baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Experimental 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCP1803-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RLD2003</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RLD2004</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RLD2005</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCP1803-3</intervention_name>
    <description>Take it once daily for 8 weeks orally.</description>
    <arm_group_label>Experimental 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RLD2003</intervention_name>
    <description>Take it once daily for 8 weeks orally.</description>
    <arm_group_label>Active Comparator 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RLD2004</intervention_name>
    <description>Take it once daily for 8 weeks orally.</description>
    <arm_group_label>Active Comparator 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RLD2005</intervention_name>
    <description>Take it once daily for 8 weeks orally.</description>
    <arm_group_label>Active Comparator 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPP2003-3</intervention_name>
    <description>Placebo drug. Take it once daily for 8 weeks orally.</description>
    <arm_group_label>Active Comparator 1</arm_group_label>
    <arm_group_label>Active Comparator 2</arm_group_label>
    <arm_group_label>Active Comparator 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPP2005</intervention_name>
    <description>Placebo drug. Take it once daily for 8 weeks orally.</description>
    <arm_group_label>Experimental 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with essential hypertension whose blood pressure measured in visit1&#xD;
             corresponds to the following conditions&#xD;
&#xD;
               -  mean sitSBP &lt;180 mmHg and mean sitDBP &lt; 110 mmHg for patients receiving any&#xD;
                  BP-lowering drug within 1 month prior to Visit 1&#xD;
&#xD;
               -  140 mmHg ≤ mean sitSBP &lt; 180 mmHg and mean sitDBP &lt; 110 mmHg for patients not&#xD;
                  receiving BP-lowering drugs within 1 month prior to Visit 1&#xD;
&#xD;
          2. Patients with essential hypertension who meet 140 mmHg ≤ mean sitSBP &lt; 180 mmHg and&#xD;
             mean sitDBP &lt; 110 mmHg at Visit 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Difference between arms greater than 20 mmHg for mean sitSBP or 10 mmHg for mean&#xD;
             sitDBP at Visit 1&#xD;
&#xD;
          2. Orthostatic hypotension with symptoms within 3 months prior to visit 1.&#xD;
&#xD;
          3. Secondary hypertensive patient or suspected to be&#xD;
&#xD;
          4. Uncontrolled diabetes mellitus(HbA1c &gt; 9%) or type I diabetes mellitus&#xD;
&#xD;
          5. Active gout or hyperuricemia (uric acid ≥ 9mg/dL)&#xD;
&#xD;
          6. Severe heart disease or severe neurovascular disease&#xD;
&#xD;
          7. Moderate or malignant retinopathy&#xD;
&#xD;
          8. Clinically significant hematological finding&#xD;
&#xD;
          9. Severe renal diseases (eGFR&lt;30mL/min/1.73m2)&#xD;
&#xD;
         10. Severe or active hepatopathy (AST or ALT ≥ 3 times of normal range)&#xD;
&#xD;
         11. Hypokalemia or Hyperkalemia(K&lt;3.5mmol/L or K ≥ 5.5mmol/L)&#xD;
&#xD;
         12. Hyponatremia or Hypernatremia(Na&lt;135mmol/L or Na ≥ 155mmol/L)&#xD;
&#xD;
         13. Hypercalcemia&#xD;
&#xD;
         14. History of malignancy tumor&#xD;
&#xD;
         15. History of autoimmune disease&#xD;
&#xD;
         16. History of alcohol or drug abuse&#xD;
&#xD;
         17. Positive to pregnancy test, nursing mother, intention on pregnancy&#xD;
&#xD;
         18. Considered by investigator as not appropriate to participate in the clinical study&#xD;
             with other reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moo-Yong Rhee, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Donggguk University Ilsan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin-A Jung, Ph.D.</last_name>
    <phone>82-2-410-9038</phone>
    <email>jajung@hanmi.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Donggguk University Ilsan Hospital</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>10326</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moo-Yong Rhee, M.D., Ph.D.</last_name>
      <phone>82-31-961-5775</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

